Abvc Biopharma (ABVC) Non Operating Investment Income (2018 - 2026)
Abvc Biopharma's (ABVC) quarterly Non Operating Investment Income came in at -$31416.0 in Q1 2026, up 38.25% YoY from -$22723.9 in Q1 2025, and up 38.25% on a QoQ basis from -$50877.0 in Q1 2025.
Abvc Biopharma (ABVC) Non Operating Investment Income (2018 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 6 years of Non Operating Investment Income data on file, last reported at -$31416.0 in Q1 2026.
- Quarterly Non Operating Investment Income rose 38.25% year-over-year to -$31416.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$163667.0 (down 24.38% YoY) and the FY2025 annual result came in at -$192759.0, up 43.17% from the prior year.
- Non Operating Investment Income improved to -$31416.0 in Q1 2026, from -$50877.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of -$31416.0 in Q1 2026 to a low of -$79057.0 in Q2 2024.
- A 3-year average of -$53783.3 and a median of -$50877.0 in 2025 frame the typical range for Non Operating Investment Income.
- The widest YoY moves for Non Operating Investment Income: up 38.25% in 2026, down 38.25% in 2026.
- Tracing ABVC's Non Operating Investment Income over 3 years: stood at -$79057.0 in 2024, then jumped by 35.65% to -$50877.0 in 2025, then jumped by 38.25% to -$31416.0 in 2026.
- The last three Non Operating Investment Income figures came in at -$31416.0 (Q1 2026), -$50877.0 (Q1 2025), and -$79057.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | -24,766.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24,766.00 |
| Jun 30, 2026 | -24,766.00 |
| Mar 31, 2026 | -31,416.00 |
| Mar 31, 2026 | -31,416.00 |
| Mar 31, 2025 | -50,877.00 |
| Mar 31, 2025 | -50,877.00 |
| Jun 30, 2024 | -79,057.00 |
| Jun 30, 2024 | -79,057.00 |
| Dec 31, 2020 | -2,317.00 |
| Dec 31, 2020 | -2,317.00 |
| Sep 30, 2020 | 665.00 |
| Sep 30, 2020 | 665.00 |
| Jun 30, 2020 | -38,937.00 |
| Jun 30, 2020 | -38,937.00 |
| Dec 31, 2019 | -27,973.00 |
| Dec 31, 2019 | -27,973.00 |
| Sep 30, 2019 | -64,689.00 |
| Sep 30, 2019 | -64,689.00 |
| Dec 31, 2018 | 288,062.00 |
| Dec 31, 2018 | 288,062.00 |